Introduction {#Sec1}
============

Atrial fibrillation is one of the most common types of arrhythmia. Currently, it occurs in approximately 2 % of the general population, but it is estimated that its incidence will increase even more \[[@CR1], [@CR2]\]. The presence of the arrhythmia is associated with an elevated risk of cardiovascular events, most of all stroke \[[@CR3]\]. It is estimated that approximately one fifth of all strokes is attributable to the atrial fibrillation and, therefore, could be avoided if patients were managed properly \[[@CR4]\]. Given the high atrial fibrillation prevalence and disabling consequences of stroke, prevention of the thromboembolic events is currently one of the key issues in treatment of atrial fibrillation patients \[[@CR3], [@CR5]\].

Current guidelines recommend planning the anticoagulation treatment individually, according to the patients' thromboembolic risk. Two tools recommended to be used in this indication are the CHADS~2~ and CHA~2~DS~2~-VASc scores. Both tools are based on easy to obtain clinical data including the presence of congestive heart failure, age, diabetes mellitus, sex, history of stroke, or vascular disease. Point values obtained in the CHADS~2~ and CHA~2~DS~2~-VASc scores give us approximate information of the annual stroke risk and, therefore, indications for anticoagulation treatment \[[@CR6], [@CR7]\].

Unfortunately, like most point scores, CHADS~2~ and CHA~2~DS~2~-VASc are likely to overlook important parameters, including comorbidities associated with elevated thromboembolic risk. One of them is obstructive sleep apnea (OSA), a sleep-disordered breathing with high prevalence in atrial fibrillation patients (estimated to be between 32 and 49 %) \[[@CR8]\]. OSA is strongly associated with hypercoagulation, which has been reported in the literature previously \[[@CR9]--[@CR11]\]. OSA influence strongly also on prevalence of hypertension, sympathetic dysregulation, or many other cardiovascular risk factors, which causes elevated risk of stroke and other thromboembolic events. The strongly elevated thromboembolic risk and mutual exacerbation of the diseases even caused that, recently, atrial fibrillation and OSA have been postulated to be components of one clinical syndrome \[[@CR12]\].

We hypothesize that the stroke risk will be higher in patients with OSA and that this relationship will be clearly shown by the results of CHADS~2~ and CHA~2~DS~2~-VASc scores in both groups of patients. The aim of the study was to determine if the occurrence of OSA in atrial fibrillation patients is associated with higher stroke risk assessed by CHADS~2~ and CHA~2~DS~2~-VASc scores.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

In accordance with the Declaration of Helsinki, the study protocol was approved by the Regional Ethics Committee. Before the study entry, a written informed consent was obtained from every study participant. Two hundred fifty-four consecutive patients hospitalized in a high-volume, tertiary University Hospital Cardiology Department were enrolled. The cause of admission in every patient was prequalification for atrial fibrillation ablation procedure. Subjects were eligible to participate in this study if they were 18 to 75 years of age without previously diagnosed OSA or central sleep apnea and no current treatment with continuous positive airway pressure (CPAP) device. Exclusion criteria included prior ablation for atrial fibrillation, untreated overt hyper- or hypothyroidism (defined according to current guidelines), myocardial infarction or decompensation of heart failure within 6 months prior to study entry, fatal condition with estimated life expectancy of ≤6 months, presence of contraindications for polygraphy study including acute and/or chronic pulmonary diseases like obstructive pulmonary disease or active tuberculosis, neuromuscular disease, hemochromatosis, severe neurologic, or psychiatric disorders \[[@CR13], [@CR14]\].

Assessment of atrial fibrillation and cardiovascular risk {#Sec4}
---------------------------------------------------------

Medical history of patients, including occurrence of cardiovascular risk factors, was taken on admission in every patient by a qualified physician. In the night following the admission, every patient underwent a whole night sleep study using a portable polygraphy device for diagnosing sleep disorder breathing (Embletta Gold; Flaga, Reykjavik, Iceland).

Diagnosis of atrial fibrillation was based on at least one arrhythmia episode recorded in a 24-h ECG Holter monitoring in 6 months prior to the study enrollment. Diagnosis of the arrhythmia was determined with respect to the European Society of Cardiology Guidelines for the management of atrial fibrillation from 2010 and its update from 2012 \[[@CR3], [@CR5]\]. Patients included in the study were prequalified for atrial fibrillation ablation; therefore, no permanent atrial fibrillation was diagnosed in the study population (permanent arrhythmia is diagnosed only if it is decided not to pursue rhythm control strategy). Paroxysmal atrial fibrillation was defined as self-terminating, usually within 48 h, which may continue for up to 7 days. Persistent atrial fibrillation was defined when arrhythmia episode either lasted longer than 7 days or required termination by cardioversion either with drugs or by direct current cardioversion \[[@CR3]\].

All patients were interviewed for history of cardiac failure, moderate to severe left ventricle systolic dysfunction, hypertension, diabetes, stroke or transient ischemic attack (TIA), and vascular disease (including myocardial infarction, complex aortic plaque, and peripheral artery disease including prior revascularization, amputation due to peripheral artery disease, or its angiographic evidence). Diagnosis of the abovementioned diseases were made basing on eligible medical records, taking prescription drugs applicable for the respective disease (i.e., hypoglycemic agents for diabetes) or as a de novo diagnosis according to current criteria.

Assessment of stroke risk {#Sec5}
-------------------------

The CHADS~2~ and CHA~2~DS~2~-VASc scores were calculated for every patient based on predefined point systems according to the current guidelines for scoring and diagnosing all mentioned conditions \[[@CR6], [@CR7]\]. In the CHA~2~DS~2~-VASc score, 2 points were assigned if a patient had a history of stroke or TIA or was ≥75 years of age. One point was assigned for the age 65--74 years, female sex, history of hypertension, diabetes, recent cardiac failure, and vascular disease (history of myocardial infarction, presence complex aortic plaque, or peripheral artery disease). In the CHADS~2~ score, 2 points are assigned for the history of stroke or TIA, and 1 point for each of the following: history of congestive heart failure, diabetes or hypertension, and age ≥75 years.

Diagnosis of OSA {#Sec6}
----------------

Polygraphy used in the study is a level 3 sleep monitoring tool according to the recommendations of the European Respiratory Society and the European Society of Hypertension \[[@CR15]\]. This kind of devices record \>4 channels including channels to detect respiratory movements or respiratory effort, airflow, heart rate, ECG, and oxygen saturation and are used for objective OSA diagnosis confirmation. All polygraphy results were scored manually according to the recommendations of the American Academy of Sleep Medicine by a qualified cardiologist specialized in sleep medicine \[[@CR16]\]. Apnea was defined as a complete cessation (residual air flow equal of \<10 % of the preceding stable breathing period) of airflow lasting ≥10 s. Obstructive breathing event occurs with complete upper airway obstruction. Hypopnea was defined as a noticeable decrease (\>30 and \<90 %) in the respiratory signal amplitude which lasted for \>10 and accompanied by desaturation (≥4 %). OSA diagnosis was made when the apnea--hypopnea index (AHI, number of apneas and hypopneas per hour) was ≥5 per hour. Patients with confirmed OSA were subsequently grouped according to OSA severity with AHI ≥ OSA severity was classified as mild when AHI ≥5 and \<15 per hour, moderate when AHI was ≥15 and ≤30 per hour, and as severe when AHI was \>30 per hour.

Statistical analysis {#Sec7}
--------------------

Data were tested for normality using the Kolmogorov--Smirnov test. Continuous data are presented as mean and 95 % confidence intervals (CI), with statistical comparisons performed with the Mann--Whitney test or Student's *t* test. Categorical variable comparison was made using either the chi-square or Fisher exact tests. A one-way analysis of variance was used to assess the impact of OSA severity according to AHI on the CHADS~2~ and CHA~2~DS~2~-VASc scores. A *p* value of less than 0.05 was considered statistically significant, whereas the confidence intervals were 95 %. All statistical calculations were performed using commercially available SAS statistical software version 8.02 (SAS Institute, Inc., Cary, NC, USA).

Results {#Sec8}
=======

The baseline characteristics of the study population are described in Table [1](#Tab1){ref-type="table"}. Of the 254 patients, 88 (34.6 %) were females. Mean age of the study population was 57.5 ± 10.0 years. Hypertension was present in 73.6 % of patients, whereas 63.4 % suffered from dyslipidemia. The prevalence of body mass index (BMI) exceeding criteria for obesity diagnosis (\>30 kg/m^2^) was 42.9 %. Paroxysmal atrial fibrillation was present in the majority of patients (69.3 %), and for the rest, persistent atrial fibrillation was diagnosed. Mean CHADS~2~ and CHA~2~DS~2~-VASc scores were, respectively, 1.0 ± 0.8 and 1.8 ± 1.4. Mean AHI value in the whole study population was 8.4 ± 10.8 per hour.Table 1Baseline characteristics of the study populationParameterValueAge (years)57.5 ± 10.0Female88 (34.6 %)Hypertension187 (73.6 %)Diabetes mellitus23 (9.1 %)Prior stroke or TIA18 (7.1 %)Dyslipidemia161 (63.4 %)Smoking26 (10.2 %)SBP (mm Hg)132.1 ± 16.9DBP (mm Hg)80.9 ± 11.1BMI \>30 kg/m^2^109 (42.9 %)Neck circumference (cm)40.3 ± 3.6Waist circumference (cm)108.4 ± 65.7Paroxysmal AF176 (69.3 %)AHI \<5 per hour133 (52.4 %)AHI ≥5 and \<15 per hour74 (29.1 %)AHI ≥15 and \<30 per hour35 (13.8 %)AHI ≥30 per hour12 (4.7 %)CHADS~2~1.0 ± 0.8CHA~2~DS~2~-VASc1.8 ± 1.4AHI (per hour)8.4 ± 10.8Values are mean ± SD or *n* (%),*AF* atrial fibrillation, *AHI* apnea--hypopnea index, *BMI* body mass index, *DBP* diastolic blood pressure, *SBP* systolic blood pressure, *SD* standard deviation, *TIA* transient ischemic attack

OSA was present in 47.6 % of patients. Details of patients' characteristics according to OSA status are presented in Table [2](#Tab2){ref-type="table"}. Patients with OSA were older (59.6 ± 7.9 vs. 55.5 ± 11.3 years; *p* = 0.008) and had higher neck (41.2 ± 3.8 vs. 39.4 ± 3.3 cm; *p* = 0.0002) and waist circumferences (108.5 ± 13.1 vs. 108.3 ± 89.2 cm; *p* \< 0.0001) than patients without OSA. Obesity was diagnosed in more patients in OSA than non-OSA group (54.5 vs. 32.3 %; *p* = 0.0006). Also, the prevalence of other comorbidities was different in patients with and without OSA. Patients with OSA more often were diagnosed with hypertension (80.2 vs. 67.7 %; *p* = 0.03), diabetes mellitus (13.2 vs. 5.3 %; *p* = 0.05), or had history of stroke (13.2 vs. 1.5 %; *p* = 0.0007) than patients without the sleep-disordered breathing condition. The form of arrhythmia that was predominant in OSA patients was persistent atrial fibrillation, whereas in patients without OSA, atrial fibrillation was more often paroxysmal (*p* = 0.02).Table 2Patients' characteristics according to the presence of obstructive sleep apneaParameterPatients without OSA (*n* = 133)Patients with OSA (*n* = 121)*p* valueAge (years)55.5 ± 11.359.6 ± 7.90.008Female52 (39.1 %)36 (29.8 %)0.15Hypertension90 (67.7 %)97 (80.2 %)0.03Diabetes mellitus7 (5.3 %)16 (13.2 %)0.05Prior stroke or TIA2 (1.5 %)16 (13.2 %)0.0007Dyslipidemia84 (63.2 %)77 (63.6 %)0.96Smoking16 (12.0 %)10 (8.3 %)0.43SBP (mm Hg)131.5 ± 17.0132.8 ± 16.80.55DBP (mm Hg)80.0 ± 10.882.0 ± 11.50.16BMI \>30 kg/m^2^43 (32.3 %)66 (54.5 %)0.0006Neck circumference (cm)39.4 ± 3.341.2 ± 3.80.0002Waist circumference (cm)108.3 ± 89.2108.5 ± 13.1\<0.0001Paroxysmal AF101 (75.9 %)75 (62.0 %)0.02CHADS~2~0.8 ± 0.61.2 ± 0.9\<0.0001CHA~2~DS~2~-VASc1.5 ± 1.12.2 ± 1.70.001Values are mean ± SD or *n* (%)*AF* atrial fibrillation, *AHI* apnea--hypopnea index, *BMI* body mass index, *DBP* diastolic blood pressure, *OSA* obstructive sleep apnea, *SBP* systolic blood pressure, *SD* standard deviation, *TIA* transient ischemic attack

General thromboembolic risk profile assessed by both CHADS~2~ and CHA~2~DS~2~-VASc scores was higher in patients with OSA than without it. Mean CHADS~2~ score in the group with and without OSA was 1.2 ± 0.9 and 0.8 ± 0.6 points, respectively (*p* \< 0.0001). In CHA~2~DS~2~-VASc scale, patients with OSA scored 2.2 ± 1.7, while the mean score in non-OSA patients was 1.5 ± 1.1 points (*p* = 0.001) (Fig. [1](#Fig1){ref-type="fig"}). Differences in thromboembolic risk remained significant even when we analyzed patients in different age strata. CHADS~2~ score in patients ≤65 years old was higher in OSA than non-OSA patients (0.7 ± 0.6 vs. 1.1 ± 0.8 points; *p* = 0.0004), similarly to patients \>65 years of age (0.9 ± 0.5 vs. 1.7 ± 1.3 points; *p* = 0.03, respectively) (Fig. [2a](#Fig2){ref-type="fig"}). The same trend was observed in respect to the mean CHA~2~DS~2~-VASc score. In patients ≤65 years old, the mean value in OSA patients was 1.2 ± 0.9 and in non-OSA patients was 1.7 ± 1.4 points (*p* = 0.03). Analysis of the group of patients older than 65 years also showed that OSA patients had higher (2.5 ± 1.0 points) CHA~2~DS~2~-VASc score than non-OSA patients (3.6 ± 1.54 points; *p* = 0.004) (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 1Mean CHADS~2~ and CHA~2~DS~2~-VASc scores in patients with and without obstructive sleep apnea (OSA)Fig. 2Relationship of mean obstructive sleep apnea (OSA) with CHADS~2~ (**a**) and CHA~2~DS~2~-VASc (**b**) scores in different age strata

In the general population, both CHADS~2~ and CHA~2~DS~2~-VASc scores seemed to correspond with OSA severity. Dividing the patients into four groups: non-OSA (with AHI \<5 per hour), mild OSA (AHI ≥5 and \<15 per hour), moderate OSA (AHI ≥15 and ≤30 per hour), and severe OSA (AHI \>30 per hour) showed that there was a significant trend towards a rise in CHADS~2~ (*p* for trend \<0.001) and CHA~2~DS~2~-VASc scores (*p* for trend \<0.001) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Trends in CHADS~2~ (**a**) and CHA~2~DS~2~-VASc (**b**) scores according to obstructive sleep apnea (OSA) severity

To perform a sensitivity analysis, we divided patients into groups with paroxysmal and permanent atrial fibrillation. We observed higher CHADS~2~ and CHA~2~DS~2~-VASc scores in all OSA patients. In permanent atrial fibrillation patients, the mean CHADS~2~ score was 0.9 ± 0.5 vs. 1.2 ± 0.8 (*p* = 0.3) for non-OSA and OSA patients, respectively, and CHA~2~DS~2~-VASc score was 1.7 ± 1.0 vs. 1.9 ± 1.6 (*p* = 0.8). In the group with paroxysmal atrial fibrillation, the mean CHADS~2~ was 0.7 ± 0.6 vs. 1.3 ± 1.0 (*p* \< 0.0001), and the mean CHA~2~DS~2~-VASc was 1.4 ± 1.1 vs. 2.4 ± 1.7 (*p* \< 0.0001) respectively.

Discussion {#Sec9}
==========

CHADS~2~ and CHA~2~DS~2~-VASc scores are simple risk assessment schemes. CHADS~2~ was developed basing on the AF Investigators and Stroke Prevention in Atrial Fibrillation (SPAF) Investigators criteria and includes stroke risk factors like recent cardiac failure, hypertension, age \>75 years, diabetes, and history of stroke or TIA \[[@CR6]\]. The presence of those factors showed to be predictive for thromboembolic risk in the population of SPAF trial \[[@CR17]\]. In all of the SPAF trials, OSA was not assessed and, therefore, could not be included in the risk model. Risk assessment scheme was developed with data from Euro Heart Survey on Atrial Fibrillation, which again does not include data on OSA \[[@CR18]\]. CHA~2~DS~2~-VASc score attributes points for history of congestive heart failure, hypertension, diabetes, stroke, vascular disease, age ≥75 or 65--74, and female sex \[[@CR7]\]. Both scores showed to predict incidence of stroke basing on the patient's score \[[@CR6], [@CR19]\]. Moreover, they showed value in predicting other complications like pulmonary embolism or coronary artery disease severity \[[@CR20], [@CR21]\]. Some authors even postulated that CHADS~2~ can be useful in predicting ischemic stroke in patients without atrial fibrillation \[[@CR22]\]. Both scores are clinically useful, but there are several disparities between them. Current guidelines encourage the use of CHA~2~DS~2~-VASc because some analyses showed that CHADS~2~ may underestimate stroke risk in patients with lower value range \[[@CR23]\]. Nevertheless, both schemes are not free from flaws, and both may underestimate real stroke risk.

Meta-analyses of prospective cohort studies show that OSA patients, similarly to atrial fibrillation patients, are more likely to suffer from stroke \[[@CR9]--[@CR11], [@CR24]\]. Moreover, sleep-disordered breathing is a predictor of all-cause mortality and recurrent vascular events following stroke \[[@CR25]\]. In our study, like in the previous observations, the occurrence of OSA was associated with older age and obesity. These two risk factors are associated not only with the occurrence of OSA but also the promotion of atrial fibrillation in the general population \[[@CR2], [@CR26], [@CR27]\]. There is a blurred line between concepts that OSA promotes atrial fibrillation, atrial fibrillation contributes to OSA development, or both conditions are caused by other common risk factors \[[@CR8]\]. Nevertheless, cardiovascular risk, including stroke risk, is altered additively by both diseases.

The concept of adding OSA as a stroke risk factor to the CHADS~2~ has been previously proposed by Yazdan-Ashoori and Baranchuk \[[@CR28]\], but literature lacked evidence from trials that were designed to support the thesis. It was proposed to include OSA in the CHADS~2~ score by allocating 1 point for OSA, and as the authors said, to rename the score CHADSS~2~ by adding an extra "S" for sleep apnea. The design of the present trial also does not provide an answer if OSA is an independent risk factor for future stroke and/or mortality in this group of patients, but it highlights two problems. First of all, in our study, OSA patients had higher CHADS~2~ and CHA~2~DS~2~-VASc scores even irrespectively of age group. This is caused by higher morbidity rates and worse general risk profile in this group of patients. Second of all, OSA is a strong stroke risk factor. Patients afflicted with OSA already are at higher risk of stroke when we do not incorporate OSA as an additional factor in the risk prediction model; it is possible that we can oversee some OSA patients with low CHADS~2~ and CHA~2~DS~2~-VASc scores who would benefit from anticoagulation therapy.

The newest data show that in spite of the current guidelines, many patients with atrial fibrillation in whom anticoagulation is required do not receive proper treatment in many European countries \[[@CR29], [@CR30]\]. In many cases, patients with atrial fibrillation are undertreated, and many of the strokes associated with OSA could have been avoided by proper risk assessment and more aggressive treatment. Some authors even propose for active screening for atrial fibrillation in all OSA patients, saying that in this high-risk group, this kind of intervention would benefit in stroke rate reduction \[[@CR31]\]. OSA screening is easy and widely applicable, while confirmation of the diagnosis with polygraphy or polysomnography becomes more accessible.

In conclusion, OSA was highly prevalent in atrial fibrillation patients. Patients with OSA have higher CHADS~2~ and CHA~2~DS~2~-VASc scores. Mean CHADS~2~ and CHA~2~DS~2~-VASc scores rise with OSA severity assessed by AHI. OSA can be a predictor of higher stroke risk in atrial fibrillation patients. All atrial fibrillation patients with OSA should be monitored more carefully for stroke risk factors and promptly introduced with anticoagulation therapy if needed. Further studies are needed to decide if OSA carries a risk beyond its most often comorbidities incorporated in the CHADS~2~ and CHA~2~DS~2~-VASc scores and if it should be included in the risk prediction schemes.
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